Amgen Inc $113.06

down -0.26


24/4/2014 09:43 AM  |  NASDAQ : AMGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get AMGN Trend Analysis - it has underperformed the S&P 500 by 18%

Partner Headlines

  1. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces ...

    Benzinga
  2. Stocks End Six-Day Win Streak As Techs Sell Off

    IBD
  3. Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles

    IBD
  4. #PreMarket Primer: Wednesday, April 23: Data From China Takes Some Pressure ...

    Benzinga
  5. AMGEN

    IBD
  6. Gilead Soars As Hep C Drug Shatters Views; Amgen Misses

    IBD
  7. Rallying Ahead of Earnings

    FoxBusiness
  8. Nasdaq, S&P 500 On Track For Sixth Straight Gain

    IBD
  9. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  10. Stocks Power Out Early Gains; Allergan Leads Drug-Maker Surge

    IBD
  11. Earnings Scheduled For April 22, 2014

    Benzinga
  12. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  13. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  14. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  15. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response ...

    Benzinga
  16. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  17. Cholesterol drug meets goal

    IBD
  18. Trial Results Lift Drug Sector

    IBD
  19. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  20. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  21. Gilead Adds To Biotech Woes

    IBD
  22. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  23. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  24. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  25. Biotech ETFs Come Back Down To Earth

    Benzinga
  26. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  27. BIOGEN IDEC

    IBD
  28. Have We Seen The Top Of The Market?

    Benzinga
  29. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  30. Amgen up on drug trial result

    IBD
  31. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  32. US Stock Futures Edge Lower Ahead Of Wholesale Trade Data

    Benzinga
  33. Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR ...

    Benzinga
  34. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  35. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  36. Insys Set To Report Q4 Earnings With Stock Surging

    IBD
  37. Why Stock Shakeouts Can Be Scary, Yet Constructive

    IBD
  38. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga
  39. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  40. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  41. France's Biosimilar Substitution May Lead to Erosion of Amgen

    Benzinga
  42. Why Mr. Cautious Is 82% Invested In Stocks

    YCharts
  43. Illumina, Alexion Lead 4 Big Caps Drawing Big Buyers

    IBD
  44. You Can No Longer Ignore Biotech

    GuruFocus
  45. Merck soars on cancer deal

    IBD
  46. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  47. Merck Misses Estimates in 4Q; Plans Increased Focus on Cancer

    FoxBusiness
  48. Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial ...

    Benzinga
  49. Pfizer, Amgen Earnings Beat

    IBD
  50. Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial ...

    Benzinga
Trading Center